Senores Pharmaceuticals Limited

  • Minimum Investment
    ₹14,136
  • Price Range
    ₹372 - ₹391
  • Issue Size
    ₹582.11 Cr
  • Lot Size
    38 shares

Proceeds of this IPO to be used for

Funding capital expenditure requirements by investment in a subsidiary, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to set up a manufacturing facility for the production of sterile injections in the Atlanta Facility

Repayment/pre-payment, in full or in part, of certain borrowings availed by the company and its subsidiaries, Havix, Ratnatris Pharmaceutical (“Ratnatris”), and Senores Pharmaceuticals Inc. (“SPI”)

Funding the working capital requirements of the company and its subsidiaries, SPI and Ratnatris

Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

Download RHP DocumentGet more in-depth details about this IPO.

Strengths & Weaknesses of Senores Pharmaceuticals Limited

US FDA approved facility

The company manufactures products for regulated markets through a US FDA-approved OSD facility in Atlanta, US. The Atlanta facility has a strong regulatory track record and has been audited and approved by the US FDA four times since the commencement of its operations.

Long-term arrangements

The company has entered into long-term marketing arrangements for a period ranging between 5-7 years with major generic pharmaceutical and marketing companies that operate in the regulated markets including Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., and Sun Pharmaceuticals Industries.

Dependent on third party partners

The company's business is dependent on the sale of products through third-party marketing partners and distributors. The loss of one or more marketing partners or distributors or the inability to maintain and increase the number of their arrangements for the marketing and distribution of its products could adversely affect the business, financial conditions, and cash flows.

Dependent on a few customers

The company derives a significant part of its revenue from a few customers. If one or more of such customers choose not to source their requirements from the company, or terminate its contracts or purchase orders, its financial condition and results of operations may be adversely affected.

Geographically concentrated

The company derives a significant portion of its revenue from its operations in the United States. A reduction in demand for its products in these regions could adversely affect the business

Financials

Earnings Per Share

Earnings Per Share (EPS) is calculated by dividing a company’s net income by its average number of outstanding shares.

No Data

Balance Sheet

A financial statement that provides details about a company’s assets, liabilities, and shareholders’ equity at a given point in time.
Particulars (In Cr)Y/Y Change
Total Current Assets--
Total Non-Current Assets--
Fixed assets--
Total assets--
Total Current Liabilities--
Total Non-Current Liabilities--
Total Capital Plus Liabilities--
Total Shareholder Funds--
Total Debt to Equity--

Cash Flow

The net amount of cash or cash equivalents being transferred in and out of a company for a specified period of time. Cashflow stems from operating, investing and financing activities.
Particulars (In Cr)Y/Y Change
Cash from Operating Activity--
Cash from Financing Activities--
Cash from Investing Activities--
Net Cash Flow--

About Senores Pharmaceuticals Limited

Senores Pharmaceuticals Ltd. was incorporated on December 26, 2017. The company is engaged in the the business of developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
  • Promoter
    Swapnil Jatinbhai Shah
  • Promoter
    Ashokkumar Vijaysinh Barot

Senores Pharmaceuticals Limited IPO FAQs

What is Senores Pharmaceuticals Limited IPO?

down-arrow
Senores Pharmaceuticals Limited IPO refers to the initial public offering of shares by Senores Pharmaceuticals Limited. It is a process by which the company offers its shares to the public for the first time, allowing individuals to become shareholders.

What is the issue size of Senores Pharmaceuticals Limited IPO?

down-arrow
For Senores Pharmaceuticals Limited IPO the issue size is ₹582 Cr. The issue size is the total value of the shares offered to the public. It represents the amount the company aims to raise through the IPO.

What is the minimum investment amount for the Senores Pharmaceuticals Limited IPO?

down-arrow
For Senores Pharmaceuticals Limited IPO the minimum investment is ₹14,136. The minimum investment for Senores Pharmaceuticals Limited IPO is the smallest amount an individual can invest to participate in the offering. It is usually determined by the company and regulatory requirements.

What is the lot size of Senores Pharmaceuticals Limited IPO?

down-arrow
For Senores Pharmaceuticals Limited IPO the lot size is 38 shares. The lot size of Senores Pharmaceuticals Limited IPO refers to the number of shares that investors need to bid for and purchase in a single transaction. It is predetermined by the company and regulators.

How to apply for Senores Pharmaceuticals Limited IPO on Share.Market?

down-arrow
To apply for Senores Pharmaceuticals Limited IPO on Share.Market, go to the home page section and click/press on the browse IPOs section to view the open and upcoming IPOs. Select the Senores Pharmaceuticals Limited IPO from the list and click on apply now. Place your bids or choose the Cut-off Price option. Enter your UPI ID and set up your mandate to place your application.

Can I pre-apply for Senores Pharmaceuticals Limited IPO?

down-arrow
Yes, investors can often pre-apply for some of the IPOs. Pre-application allows individuals to express their interest in participating in the IPO before the official subscription period begins. To pre- apply for Senores Pharmaceuticals Limited IPO on Share.Market, go to the home page section and click/press on the browse IPOs section to view the open and upcoming IPOs. Select the IPO from the list and click on pre-apply now. Once the IPO opens for subscription you can enter your UPI ID and set up your mandate to place your application.

How many days is the IPO application window open?

down-arrow
The IPO application window typically remains open for 3 days, starting from the date of the IPO opening. However, this duration can vary depending on the specific IPO and the regulatory requirements.

Till what time can I apply for an IPO on the last day on Share.Market?

down-arrow
You can apply for the IPO till 3 PM on the last day of application on Share.Market.

What is the allotment date of Senores Pharmaceuticals Limited IPO?

down-arrow
For Senores Pharmaceuticals Limited IPO the allotment date is December 26, 2024. The allotment date of Senores Pharmaceuticals Limited IPO is the date on which shares are allocated to the successful bidders. It marks the distribution of shares to investors.

What are the open and close dates of Senores Pharmaceuticals Limited IPO?

down-arrow
For Senores Pharmaceuticals Limited IPO, the subscription opens on December 20, 2024 and closes on December 24, 2024. The open and close dates of an IPO indicate the period during which investors can submit their bids to participate in the offering.
Bidding Ongoing
-
Total Subscription
93.32x Oversubscribed
Bidding Ongoing
-
Total Subscription
93.32x Oversubscribed